Hattie Hayes

Elias Kahan speaks about his ARVO poster, "Contact specular microscopy reliably images the same location of the corneal epithelium."

Susana Chung, OD, PhD, spoke with us to discuss her presentation titled, "How similar is reading with central vision loss to reading in normal peripheral vision?" at this year's ARVO meeting held in Seattle, Washington, from May 5 to May 9.

Antonio Filipe Macedo, OD, MSc, PhD, sat down to discuss his presentation at this year's ARVO meeting held in Seattle, Washington, about vision-related activity difficulties in people diagnosed with neovascular age-related macular degeneration (nAMD)and vision impairment.

Prof Tadayoni was a much-admired leader, researcher, surgeon and EURETINA President

The European Commission is expected to make a decision about the application before the end of June.

Retina specialists Giuseppe Querques, MD, PhD, and Paolo Lanzetta, MD, debate at the Congress on Controversies in Ophthalmology

At this year's Congress on Controversies in Ophthalmology, keynote speaker Ursula Schmidt-Erfurth, MD, addressed the clinical use of artificial intelligence

The approval marks the first new steroid on the ophthalmic market in more than 15 years.

Sir Jules Thorn Charitable Trust's investment will support a state-of-the-art, eye health research facility, opening in 2027.

Dr. Jennifer Lim reveals new data on Angiopoietin-2 inhibition as a target for addressing nAMD and DME.

In conversation with Ophthalmology Times Europe, Anat Loewenstein, MD, illuminates the outcomes of using an AI-based fluid quantification for remote retina monitoring and analysis.

Dr. Carl Regillo provided an overview of topline results and a deep dive into subgroup analyses of DAVIO 2 trial data.

The European Union approval applies to aflibercept 8 mg for treatment of nAMD and DME.

A review of Ophthalmology Times Europe's most important content from throughout the year.

In the clinical trial, Oxurion’s novel PKal Inhibitor, THR-149, did not meet its primary endpoint.

Mark Blecher, MD, spoke with the Ophthalmology Times team about his poster addressing retinal visualization and patients who've had small aperture IOL implantation at this year's American Academy of Ophthalmology meeting.

Charles Wykoff, MD, PhD, spoke with the Ophthalmology Times team about the GALE study looking at pegcetacoplan for the management of geographic atrophy at this year's American Academy of Ophthalmology meeting.

Biocon’s YESAFILI is intended for treatment of a number of ocular conditions, including neovascular AMD, visual impairment due to myopic choroidal neovascularisation, visual impairment due to DME and visual impairment due to macular edema secondary to retinal vein occlusion.

The endorsement follows FDA approval in the United States this summer.

Mary Elizabeth Hartnett, MD, FACS, discussed the impact of blindness and vision loss on women in the United States.

The new range of pure and premixed gases are intended for medium-term use in retinal surgery.

Ali Erginay, MD, of Lariboisière Hospital in Paris, France, discusses his EURETINA presentation, "Introducing optomap® Ultra-widefield Colour Red-Green-Blue Multimodal Imaging."

Our team spoke to Varun Chaudhary, MD, about his EURETINA presentation, titled "Systematic Review and Metanalysis in Macular Hole RCTs – Posturing after Macular Hole Surgery."

Novartis acquired Gyroscope Holdings Limited from Syncona in February 2022.

The non-profit will partner with the imaging company to prevent blindness and fund new retinoblastoma research.

European Medicines Agency issued approval for a Clinical Trial Application of its new gene therapy, VG901, which uses an adeno-associated virus vector to treat CNGA1-associated retinitis pigmentosa.

The study met its primary efficacy endpoint for the neovascular age-related macular degeneration (nAMD) treatment.

Tenpoint’s aim is to reverse vision loss by generating specialized ocular cell types, both ex vivo and in vivo.

Margaret Chang, MD, MS, spoke with Modern Retina to give an update on avacincaptad pegol for geographic atrophy.